Marathon's cheap, old steroid breezes through the FDA for Duchenne MD, and gets priced at $89K

Jef­frey Aronin, Marathon

For a sim­ple sys­temic steroid that is cheap and eas­i­ly avail­able out­side the US, de­flaza­cort has re­ceived un­usu­al­ly care­ful sup­port from the FDA, breez­ing through a reg­u­la­to­ry process that has be­dev­iled sev­er­al de­vel­op­ers try­ing to ad­dress the root cause of the dis­ease.

De­flaza­cort won a pri­or­i­ty re­view from the agency as a new ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy — cut­ting four months off the reg­u­la­to­ry process — along with an or­phan drug des­ig­na­tion and rare pe­di­atric dis­ease sta­tus. And to­day, the FDA hand­ed Marathon Phar­ma­ceu­ti­cals a green light to start mar­ket­ing the drug to all boys 5 and old­er whose lives are be­ing slow­ly de­stroyed by the dis­ease.

The cor­ti­cos­teroid will be sold as Em­flaza af­ter one study in­volv­ing 196 DMD pa­tients in­di­cat­ed that it could im­prove the strength of pa­tients with this dis­ease. In an­oth­er tri­al with 29 male pa­tients that last­ed 104 weeks, the FDA re­port­ed, “de­flaza­cort demon­strat­ed a nu­mer­i­cal ad­van­tage over place­bo on an as­sess­ment of av­er­age mus­cle strength.”

The larg­er of those two stud­ies was com­plet­ed 21 years ago, ac­cord­ing to an ab­stract post­ed in Neu­rol­o­gy last year.

For that, the com­pa­ny plans to price the drug at $89,000 a year, ac­cord­ing to the Chica­go Tri­bune, more than $88,oo0 a year more than what Cana­di­ans would pay for the same drug. But like oth­er cas­es in­volv­ing price goug­ing, the com­pa­ny went on to de­fend the price, say­ing that in­sur­ers will cov­er most of the price.

In ad­di­tion to the ap­proval, Marathon wins a rare pe­di­atric dis­ease pri­or­i­ty re­view vouch­er. These vouch­ers have fetched hun­dreds of mil­lions of dol­lars from drug com­pa­nies look­ing for a quick and sure way to slash four months off of one of their own drug re­views.

De­flaza­cort has been avail­able in coun­tries around the world for decades.

Cur­rent­ly, you can buy de­flaza­cort from on­line phar­ma­cies in Cana­da for less than a buck a pill. Un­til fair­ly re­cent­ly it was sold by Shire in the UK, for ex­am­ple, as Cal­cort in 6 mg tablets and used to treat a va­ri­ety of chron­ic au­toim­mune con­di­tions like rheuma­toid arthri­tis. (A spokesper­son for Shire says that the drug changed hands.) But be­cause it’s nev­er been ap­proved in Amer­i­ca, where oth­er steroids have been avail­able for those same con­di­tions, it gets the full reg­u­la­to­ry treat­ment in the US.

One Duchenne mom emailed me to say that she felt her fam­i­ly was be­ing held “hostage” by Marathon, af­ter be­ing able to buy the drug for a thou­sand dol­lars a year. And more crit­i­cism be­gan to sur­face on Fri­day, as the Wall Street Jour­nal re­port­ed that Chris­tine Mc­Sh­er­ry, who runs the non­prof­it Jett Foun­da­tion, said she is “dis­ap­point­ed that Marathon in­creased my cost for the drug by more than $87,000 a year.” A num­ber of pa­tient ad­vo­cates said they were wor­ried es­pe­cial­ly for fam­i­lies with high de­ductible in­sur­ance plans.

De­flaza­cort now joins a list of con­tro­ver­sial meds that have been ac­quired and then sold at an as­tro­nom­i­cal markup. Mar­tin Shkre­li be­came the poster child of the pric­ing de­bate with his 5,000% price hike on Dara­prim, an­oth­er old gener­ic drug that tar­gets a rare con­di­tion, which came with­out any ad­di­tion­al re­search. And ex­ec­u­tives at Valeant and My­lan were hauled in front of law­mak­ers last year and grilled on their own pric­ing tac­tics for ag­ing prod­ucts.

None of it is against the law in the US, though, which is one rea­son why it’s so con­tro­ver­sial. The FDA is re­quired by law to be ag­nos­tic on pric­ing is­sues.

“This is the first treat­ment ap­proved for a wide range of pa­tients with Duchenne mus­cu­lar dy­s­tro­phy,” said Bil­ly Dunn, MD, di­rec­tor of the Di­vi­sion of Neu­rol­o­gy Prod­ucts in the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search. “We hope that this treat­ment op­tion will ben­e­fit many pa­tients with DMD.”

Up un­til Marathon, though, Duchenne MD has been a com­bat zone at the FDA.

Sarep­ta won a con­tro­ver­sial ap­proval for its DMD drug last year af­ter fight­ing for years to get an OK based on da­ta from a tiny, bad­ly flawed study. Their ap­proval came with a la­bel that tells pa­tients that the com­pa­ny has yet to gain clear ev­i­dence of ef­fi­ca­cy. PTC was shut out, much to their cha­grin. And Bio­Marin‘s dris­apersen was shown the door as well.

Marathon did not re­spond to my queries. The biotech is run by CEO Jef­frey Aronin, who start­ed Ova­tion and sold it to Lund­beck for $900 mil­lion in 2009.

I asked the FDA why the drug war­rant­ed VIP ap­proval. Their re­sponse:

De­flaza­cort has nev­er been ap­proved for any use in the Unit­ed States. Un­der U.S. law, it was re­viewed as a “new drug” and as­sessed for safe­ty and ef­fi­ca­cy for the spe­cif­ic con­di­tions of use in the la­bel­ing (pre­scrib­ing in­for­ma­tion). Ver­sions of de­flaza­cort are avail­able in some coun­tries for oth­er in­di­ca­tions, but not for DMD.  The U.S. ap­proval is the first any­where for DMD. The FDA-ap­proved prod­uct la­bel­ing in­cludes safe­ty and clin­i­cal in­for­ma­tion spe­cif­ic to the drug’s use in DMD.  If a drug meets the statu­to­ry re­quire­ments for or­phan drug des­ig­na­tionex­pe­dit­ed pro­grams, and rare pe­di­atric dis­ease des­ig­na­tion, then a spon­sor is el­i­gi­ble to re­ceive those ben­e­fits.

“We are in a new era in the treat­ment of Duchenne mus­cu­lar dy­s­tro­phy. For the first time, pa­tients in the U.S. with Duchenne will have wide­spread ac­cess to an FDA ap­proved med­i­cine that is in­di­cat­ed for all ge­net­ic forms of the con­di­tion. We are pleased that this de­vel­op­ment will help pa­tients with this dis­ease stay stronger longer,” said Tim­o­thy M. Cun­niff, Pharm.D., Ex­ec­u­tive Vice Pres­i­dent, Re­search & De­vel­op­ment, Marathon Phar­ma­ceu­ti­cals, in a state­ment.

 

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

Novartis is always one of the industry’s biggest R&D spenders. As they often do toward the end of each year, company execs are highlighting the drugs they expect will most likely be winners in 2021.

And they’re also dreaming about some potential big-time lottery tickets.

As part of its annual investor presentation Tuesday, where the company allows investors and analysts to virtually schmooze with the bigwigs, Novartis CEO Vas Narasimhan will outline what he thinks are the pharma’s “Wild Cards.” The slate of five experimental drugs are those that Novartis hopes can be high-risk, high-reward entrants into the market over the next half-decade or so, and cover a wide range of indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pur­due Phar­ma pleads guilty in fed­er­al Oxy­Con­tin probe, for­mal­ly rec­og­niz­ing it played a part in the opi­oid cri­sis

Purdue Pharma, the producer of the prescription painkiller OxyContin, admitted Tuesday that, yes, it did contribute to America’s opioid epidemic.

The drugmaker formally pleaded guilty to three criminal charges, the AP reported, including getting in the way of the DEA’s efforts to combat the crisis, failing to prevent the painkillers from ending up on the black market and encouraging doctors to write more painkiller prescriptions through two methods: paying them in a speakers program and directing a medical records company to send them certain patient information. Purdue’s plea deal calls for $8.3 billion in criminal fines and penalties, but the company is only liable for a fraction of that total — $225 million.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

Ever since President Donald Trump floated the idea of using state-sponsored importation to lower drug prices, PhRMA has made its opposition abundant. Not only is the proposal dangerous and futile,  but the trade group has also argued that it may even be illegal.

Now that the FDA has issued its final rule permitting states to bring certain drugs from Canada, PhRMA is taking the government to court — just a few days before the rule is slated to take effect.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

The flu virus (CDC)

Roche tacks on an­oth­er Xofluza in­di­ca­tion as flu sea­son meets pan­dem­ic

Xofluza was heralded as the first new flu drug in 20 years when it got the FDA OK back in 2018. But even so, Roche saw tough competition from cheaper Tamiflu generics that appeared to be nearly as — if not just as — effective.

Now, the pharma says the drug also can be used to prevent influenza after exposure, snagging a new approval and adding to Xofluza’s appeal as flu season meets the pandemic.

A poll sug­gests vac­cine da­ta boost­ed Pfiz­er's pub­lic im­age, but oth­er da­ta point to long road ahead

For much of the pharmaceutical industry, the pandemic presented an opportunity: to prove their value to the world and turn public opinion around on a business much of the country had come to disdain.

That theory — that helping pull the country from a pandemic could neutralize years of anger over high drug prices — was put to its biggest test this month, as three different drugmakers announced data from their Covid-19 vaccines, offering the first major evidence that industry-built inoculations could turn the tide of the outbreak in the US.